Short answer
Spero Therapeutics Inc (SPRO) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Patrick Vink resigned November 10 after 11 years, without reported disputes, creating a Class II board vacancy.
Spero Therapeutics Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Patrick Vink resigned November 10 after 11 years, without reported disputes, creating a Class II board vacancy
- William Ho appointed to fill the Class II seat, adding clinical development and immunotherapy expertise
- Ho joins the Development Committee, potentially strengthening oversight of Spero’s therapeutic pipeline
- Director compensation: $45,000 annual cash retainers plus an option for 100,000 shares vesting monthly over one year
- Ho’s prior RAPT role included programs contributing to GSK’s $2.2 billion acquisition, enhancing his transaction and development credentials
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Spero Therapeutics Inc 8-K filings
Get the next SPRO 8-K as it lands
Follow SPRO for push alerts, or ask the research agent what this filing means.